AcelRx Pharmaceuticals Inc (ACRX) Receives $7.89 Consensus Price Target from Analysts

Shares of AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) have been given a consensus rating of “Buy” by the nine ratings firms that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and eight have issued a buy rating on the company. The average 1 year price target among analysts that have covered the stock in the last year is $7.89.

Several brokerages have recently weighed in on ACRX. Zacks Investment Research upgraded shares of AcelRx Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, December 14th. Oppenheimer reiterated a “hold” rating on shares of AcelRx Pharmaceuticals in a research note on Monday, October 15th. Cantor Fitzgerald set a $8.00 price objective on shares of AcelRx Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, October 25th. Finally, HC Wainwright reiterated a “buy” rating and issued a $9.00 price objective on shares of AcelRx Pharmaceuticals in a research note on Wednesday, December 12th.

In other news, insider Pamela P. Palmer bought 16,000 shares of the firm’s stock in a transaction on Monday, November 19th. The shares were bought at an average price of $3.07 per share, for a total transaction of $49,120.00. Following the purchase, the insider now owns 472,134 shares in the company, valued at $1,449,451.38. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Vincent J. Angotti bought 10,000 shares of the firm’s stock in a transaction on Wednesday, December 12th. The shares were purchased at an average price of $2.99 per share, for a total transaction of $29,900.00. Following the purchase, the chief executive officer now owns 51,040 shares in the company, valued at approximately $152,609.60. The disclosure for this purchase can be found here. In the last 90 days, insiders have acquired 60,310 shares of company stock worth $176,980. 25.50% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. lifted its position in AcelRx Pharmaceuticals by 2.7% during the 2nd quarter. BlackRock Inc. now owns 673,115 shares of the specialty pharmaceutical company’s stock worth $2,271,000 after buying an additional 17,737 shares in the last quarter. FMR LLC lifted its position in AcelRx Pharmaceuticals by 1,094.6% during the 2nd quarter. FMR LLC now owns 298,644 shares of the specialty pharmaceutical company’s stock worth $1,008,000 after buying an additional 273,644 shares in the last quarter. Renaissance Technologies LLC bought a new stake in AcelRx Pharmaceuticals during the 2nd quarter worth about $1,676,000. Lincoln Capital Corp lifted its position in AcelRx Pharmaceuticals by 83.3% during the 3rd quarter. Lincoln Capital Corp now owns 62,775 shares of the specialty pharmaceutical company’s stock worth $242,000 after buying an additional 28,525 shares in the last quarter. Finally, Creative Planning lifted its position in AcelRx Pharmaceuticals by 256.1% during the 3rd quarter. Creative Planning now owns 45,222 shares of the specialty pharmaceutical company’s stock worth $174,000 after buying an additional 32,522 shares in the last quarter. Institutional investors own 10.66% of the company’s stock.

Shares of NASDAQ:ACRX opened at $2.61 on Friday. AcelRx Pharmaceuticals has a twelve month low of $1.65 and a twelve month high of $5.05. The company has a market capitalization of $170.24 million, a PE ratio of -2.37 and a beta of 2.02.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last issued its quarterly earnings data on Monday, November 5th. The specialty pharmaceutical company reported ($0.21) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.20) by ($0.01). The firm had revenue of $0.38 million for the quarter, compared to analysts’ expectations of $1.10 million. On average, research analysts expect that AcelRx Pharmaceuticals will post -0.85 earnings per share for the current fiscal year.

AcelRx Pharmaceuticals Company Profile

AcelRx Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain.

See Also: How the Consumer Price Index (CPI) is calculated?

Analyst Recommendations for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply